| __timestamp | Celldex Therapeutics, Inc. | Gilead Sciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 104381000 | 2854000000 |
| Thursday, January 1, 2015 | 100171000 | 3014000000 |
| Friday, January 1, 2016 | 102726000 | 5098000000 |
| Sunday, January 1, 2017 | 96171000 | 3734000000 |
| Monday, January 1, 2018 | 66449000 | 5018000000 |
| Tuesday, January 1, 2019 | 42672000 | 9106000000 |
| Wednesday, January 1, 2020 | 42534000 | 5039000000 |
| Friday, January 1, 2021 | 53311000 | 5363000000 |
| Saturday, January 1, 2022 | 82258000 | 4977000000 |
| Sunday, January 1, 2023 | 118011000 | 6923000000 |
| Monday, January 1, 2024 | 5907000000 |
Data in motion
In the ever-evolving world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Gilead Sciences, Inc. and Celldex Therapeutics, Inc. have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Gilead Sciences consistently allocated a significant portion of its resources to R&D, with expenditures peaking in 2019 at approximately $9.1 billion. This represents a staggering 220% increase compared to Celldex's highest spending year in 2023, where they invested around $118 million.
Celldex, while smaller in scale, has shown a steady commitment to innovation, with R&D spending increasing by nearly 180% from 2019 to 2023. This growth underscores their strategic focus on developing cutting-edge therapies. As the biotech landscape continues to shift, these spending patterns highlight the diverse strategies companies employ to drive innovation and maintain competitive advantage.
Analyzing R&D Budgets: Eli Lilly and Company vs Gilead Sciences, Inc.
R&D Insights: How Novo Nordisk A/S and Gilead Sciences, Inc. Allocate Funds
Research and Development Expenses Breakdown: Johnson & Johnson vs Gilead Sciences, Inc.
Sanofi or Gilead Sciences, Inc.: Who Invests More in Innovation?
R&D Insights: How Gilead Sciences, Inc. and Amicus Therapeutics, Inc. Allocate Funds
Analyzing R&D Budgets: Gilead Sciences, Inc. vs Veracyte, Inc.
Research and Development Investment: Gilead Sciences, Inc. vs Iovance Biotherapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Sarepta Therapeutics, Inc. and Celldex Therapeutics, Inc.
Research and Development Investment: Axsome Therapeutics, Inc. vs Celldex Therapeutics, Inc.
ACADIA Pharmaceuticals Inc. vs Celldex Therapeutics, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Agios Pharmaceuticals, Inc. and Celldex Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Dynavax Technologies Corporation and Celldex Therapeutics, Inc.